

Drug Development: Role of the FDA and Sponsor Module Resources

Selected References

Investigational Device Exemptions, 21 C.F.R. pt. 812 (2014). Retrieved from

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=812dsf>.

Investigational New Drug Application, 21 C.F.R. §§ 312.50–312.70 (2024). Retrieved from

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.4>.

U.S. Food and Drug Administration. (2022). How drugs are developed and approved. Retrieved from <https://www.fda.gov/drugs/development-approval-process-drugs/how-drugs-are-developed-and-approved>.

U.S. Food and Drug Administration Office of Good Clinical Practice. (2010, May). Information sheet guidance for sponsors, clinical investigators, and IRBs: Frequently asked questions—Statement of investigator (Form FDA 1572). Retrieved from

<http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm214282.pdf>.

FDA History:

- [The Story of the Laws Behind the Labels](#)
- [Milestones in U.S. Food and Drug Law](#)